Drug: Ibrutinib (Imbruvica, Pharmacyclics/Janssen)
Status: Granted a new indication for ibrutinib for the treatment of adults with chronic graft-versus-host disease (cGVHD) after failure of 1 or more lines of systemic therapy
Significant Information:
- With this approval, the Bruton’s tyrosine kinase inhibitor ibrutinib becomes the first and only therapy specifically approved for adults with cGVHD, a serious and debilitating potential consequence of hematopoietic cell transplant.